Kornimate/medical-research-clean huggingface dataset:
study of venous endothelial cells in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: heart disease is the major contributor of early death in rheumatoid arthritis (ra) and is not influenced by traditional risk factors. blood vessel dysfunction has been associated with heart disease and complications such as heart attack. the vessel dysfunction is thought to be mediated in part to inflammation. ra patients have evidence of vessel dysfunction seen on ultrasound that improves after medications are given. the purpose of this study is to evaluate patients with controlled or uncontrolled rheumatoid arthritis to determine if there is a difference in the protein expression in the cells that line the blood vessels compared to healthy people.

the study will consist of a cross sectional analysis of venous endothelial cells in rheumatoid arthritis patients who have controlled or uncontrolled disease and healthy controls. we will collect venous endothelial cells by placing an iv in antegrade position in the forearm and a thin wire will be inserted to collect the cells from the inner lining of the vein. the cells will processed and stained for markers of endothelial function and oxidative stress including endothelial nitric oxide synthase (enos), phospho-enos, nuclear factor kappa b (nfκb), and nitrotyrosine using immunofluorescence technique. flow mediated dilation (fmd) by ultrasound of the brachial artery on the contralateral arm will be used as an additional marker of endothelial function. a blood sample will be taken for analysis of inflammatory markers (sedimentation rate, c-reactive protein) and cytokine analysis (il-1, il-6, tnfa) by cytokine bead array and flow cytometry.

Eligibility criteria:
inclusion criteria: rheumatoid arthritis: * age 18-75 years * rheumatoid arthritis defined by 1987 american college of rheumatology criteria * attending clinic at university of texas southwestern aston clinic for rheumatology or parkland arthritis clinic. healthy controls: - age 18-75 years. exclusion criteria: rheumatoid arthritis: * insulin dependent diabetes * cardiovascular or cerebrovascular disease * tobacco use in last 24 months * uncontrolled blood pressure * uncontrolled cholesterol * pregnant or nursing * prednisone greater than 10mg per day * stable methotrexate dose for less than 4 weeks * undergoing infliximab infusions healthy controls: * insulin dependent diabetes * cardiovascular or cerebrovascular disease * tobacco use in last 24 months * uncontrolled high blood pressure * uncontrolled cholesterol * pregnant or nursing

Keywords: rheumatoid arthritis
exercise training effect in patients with hf and pef

Conditions: Heart Failure

Summary: the purpose of this is to develop and implement a pilot study that will demonstrate the ability to recruit, enroll, retain, conduct exercise training, and collect pre and post outcomes on the effect of exercise training on quality of life (qol) and exercise capacity in patients with a diagnosis of heart failure with preserved ejection fraction (hfpef).


Eligibility criteria:
inclusion criteria: * age \> 55 years (interested in capturing mean ages close to age 65 as many hf initiatives are based on this age group and hf development increases with aging). * diagnosis of hfpef stable nyha stage ii- iii with an ef of ≥ 45% * stabilized on cardiac medications and post hospitalization \> 4 weeks * ability to participate in exercise testing and training. * referral from cardiologist or primary care physician. exclusion criteria: * unstable angina * uncontrolled diabetes * moderate to severe aortic stenosis * uncontrolled hypertension systolic bp\>150 mm hg or diastolic bp \>100 mm hg * valvular heart disease * untreated coronary artery stenosis \>50% * arrhythmias * pulmonary disease/copd * dementia or cognitive impairment * vad or transplant planned in next 6 months. * current or recent participation in a cardiac rehab program within the last six months.
ocular surface metabolo-lipidomics in lateral amyotrophic sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: amyotrophic lateral sclerosis (als) is the most common neurodegenerative disease affecting the motor neuron. currently, there is no diagnostic test and no examination that can predict the evolution of this pathology. the search for diagnostic and prognostic biomarkers is therefore essential for a better understanding of the pathophysiology of als, which remains poorly understood, and also for better clinical management. the ocular surface, made up of liquid elements, tears, and cells, is an accessible anatomical-physiological entity that has demonstrated its usefulness in the identification of biomarkers in neurodegenerative diseases such as parkinson's or alzheimer's. to date, no study has explored the ocular surface as a biomarker in als


Eligibility criteria:
case group selection criteria : inclusion criteria: * patient with clinically defined or probable primary als according to airlie house criteria(1) * familial or sporadic form * ≥18 years of age * patient affiliated with a social security plan * informed consent signed by the patient exclusion criteria: * motor neuron disease mimicking als * pregnant or breastfeeding woman * treatment that may have a neuroprotective effect * any eye drops or treatments that may interfere with tear production * lens wearer * eye surgery ≤3 months * any ocular pathology other than ametropia, oculomotor disorder, amblyopia * any general pathology other than als with ocular repercussions * protective measure of guardianship or curators control group selection criteria: inclusion criteria: * no diagnosed neurological pathology * ≥18 years of age * patient affiliated with a social security plan * informed consent signed by the participant exclusion criteria: * pregnant or breastfeeding woman * treatment likely to have a neuroprotective effect * any eye drops or treatments that may interfere with tear production * lens wearer * eye surgery ≤3 months * any ocular pathology except ametropia, oculomotor disorder, amblyopia * any general pathology with ocular repercussions * protective measure of guardianship or curator

Keywords: amyotrophic lateral sclerosis biomarkers ocular surface tear
galantamine improves motor and sensory dysfunction in patients with acute ischemic stroke

Conditions: Acute Ischemic Stroke AIS

Summary: although mechanical thrombectomy or thrombolytic therapy for large vessels can achieve a revascularization rate (tici ≥2b) of over 90%, 30-50% of patients still exhibit poor functional outcomes. this phenomenon of "ineffective reperfusion" suggests that microcirculatory dysfunction plays a decisive role in post-stroke neural injury. therefore, it is necessary to combine brain protection strategies with microcirculatory reperfusion therapy to improve the functional prognosis of stroke patients. as an acetylcholinesterase inhibitor (achei), galantamine has been widely recognized for its role in improving cerebral blood flow in ischemic stroke (is). galantamine has demonstrated good safety in treating sensory and motor dysfunction caused by neurological diseases or trauma. to this end, the applicant will conduct an international-standard, randomized controlled clinical trial with conventional treatment as a comparator to evaluate the efficacy of galantamine in improving motor and sensory dysfunction in patients with acute ischemic stroke (ais).


Eligibility criteria:
inclusion criteria: * diagnosis of acute ischemic stroke within 72h of symptom onset * a score of 4-25 points on the national institute of health stroke scale (nihss) * the mrs score before stroke is 0-1 * patient and family members sign informed consent exclusion criteria: * cranial imaging examinations confirm the presence of diseases causing similar symptoms such as brain tumors, encephalitis, brain abscess, etc., or confirm hemorrhagic cerebral infarction, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc * patients with active bleeding or bleeding tendency, malignancies, severe liver (the serum level of ast and/or alt \> 2 times the upper limit of normal), or renal failure (the serum level of creatinine \> 1.5 times the upper limit of normal or gfr \< 40 ml/min/1.73m2) * elderly people with weak constitutions or patients complicated with infections * patients with a history of mental illness or severe dementia * a significant history of drug or alcohol abuse * allergic constitution, or allergic to two or more drugs or foods * pregnancy, lactation, or planning to get pregnant * patients who are currently participating in or have participated in other clinical trials within the past 1 month * currently using or having used other cholinesterase inhibitor drugs within the past 3 months * having taken galantamine within 1 month before randomization, or being required to take galantamine for other diseases within the next 90 days * patients with epilepsy, hyperkinesia, mechanical intestinal obstruction, bronchial asthma, angina pectoris, bradycardia, or glaucoma * individuals with contraindications to mri examination * individuals who are allergic to the ingredients of the administered drug
digital storytelling-role play for ethical behaviours to protect patient rights and ethical sensitivity

Conditions: Analyses, Ethical; Digital Storytelling; Role Playing; Nursing Students; Ethics Education; Ethical Sensitivities; Ethical Behavior

Summary: this study aimed to investigate the effect of an ethics education using role-play and digital storytelling, on nursing students' ethical behaviours to protect patient's rights and ethical sensitivity. * is role-playing in ethics education effective in improving students' behaviours to protect patients' rights? * is role-playing in ethics education effective in improving students' ethical sensitivity? * is digital storytelling in ethics education effective in improving students' behaviours towards protecting patients' rights? * is digital storytelling in ethics education effective in developing students' ethical sensitivity? the researchers will compare the mean scores of the ethical behaviours toward protecting patient rights scale and ethical sensitivity scale to see whether role-playing and digital storytelling methods in ethics education have an effect on nursing students' ethical behaviours and ethical sensitivity towards protecting patient rights. * all groups will participate in the theoretical lectures of ethics education for a total of five weeks, three hours a week. * the theoretical lectures will consist of examination of ethics and related concepts, ethical principles, professional values in nursing, relationship between care and ethics, ethical problems and ethical approaches. * one week after the theoretical lecture, all groups will participate in a two-week practice phase, three hours a week. * each group will be divided into small groups of 6-7 people. * the intervention i group will conduct an ethical case analysis involving an ethical problem given to them by the researchers in the classroom environment every week and will discuss the analysis using the role-play method in the ethics committee to be formed after the session. * intervention ii group will discuss the ethical case analyses with ethical problems written by themselves by coming together outside the classroom environment. * each small group of 6-7 people will present their ethical case analyses to other group members in the classroom through digital storytelling. * the control group will continue the standard education.


Eligibility criteria:
inclusion criteria: * first-time registration in the course * being a volunteer exclusion criteria: * non-native speakers of the country's native language * previous graduation from any health-related university

Keywords: digital storytelling role playing ethics education ethical sensitivity ethical behavior
randomized, double-blind study to evaluate the tolerability of 2 different titration methods of rivastigmine patch in ad patients (mmse 10-20)

Conditions: Alzheimer's Disease

Summary: to evaluate the tolerability, safety and efficacy of 3-step titration versus 1-step titration of rivastigmine patch in the japanese population.


Eligibility criteria:
inclusion criteria: * a diagnosis of dementia of the alzheimer's type according to the dsm-iv criteria * a clinical diagnosis of probable ad according to nincds/adrda criteria * an mmse score of ≥ 10 and ≤ 20 at baseline exclusion criteria: * any medical or neurological conditions other than ad that could explain the patient's dementia * a current diagnosis of probable or possible vascular dementia * a score of \> 5 on the modified hachinski ischemic scale (mhis) * a current dsm-iv axis 1 diagnosis that may interfere with the evaluation of the patient's response to study medication. * treated with donepezil or galantamine within last 4 weeks before the efficacy assessment at baseline. * an advanced severe progressive or unstable disease of any type that may interfere with efficacy and safety assessments or put the patient's at special risk * other protocol-defined inclusion/exclusion criteria may apply.

Keywords: rivastigmine, alzheimer's disease, transdermal patch
epidemiology of hearing loss in diabetic and non-diabetic veterans

Conditions: Diabetes; Tinnitus; Hearing Loss

Summary: the purpose of this study is to determine if individuals with diabetes are at increased risk of hearing impairment or tinnitus (the perception of ringing or noises in the ears or head). an important goal of this research is also to obtain a better understanding of possible interactions between hearing disorders and other chronic conditions, such as diabetes. participation in this research will be for a few hours only, to be scheduled at the participant's convenience and according to the testing schedules of the different clinics involved.


Eligibility criteria:
any participants over 21 years of age and under 80 who do not have an end-stage disease
bip ett clinical tolerability, safety and performance study

Conditions: Endotracheal Intubation During Surgery; Hospital Acquired Infections

Summary: the objective of the study is to determine bactiguard coated bip endotracheal tube´s tolerability, safety and performance and compare it to a standard un-coated endotracheal tube.


Eligibility criteria:
inclusion criteria: * adult men and women \>=18 years of age * are, in opinion of the investigator able to communicate with and understand the trial personnel and comply with the requirements of the trial (e.g. fill in questionnaire) * requiring endotracheal intubation \>=3 h for elective surgery of upper gastrointestinal tract with a tube size of 7 or 8 * has signed informed consent exclusion criteria: * known transmissive blood disease * known multiresistant bacterial colonization * current and continuous treatment by immunomodulating therapies - e.g. systemic (or inhalation) use of cortisone or nsaids * ongoing respiratory infection

Keywords: medical device endotracheal tube(s), ett bactiguard coated ett tolerability safety performance bacterial colonization on ett surface hospital acquired infections, hai ventilator associated pneumonia, vap
laparoscopic burch colposuspension versus midurethral sling for treatment of female stress urinary incontinence a randomized controlled trial

Conditions: Treatment of Female Stress Urinary Incontinence

Summary: to compare the laparoscopic burch colposuspension with the midurethral slings (tvt, tot) for treatment of female stress urinary incontinence as regard efficacy and safety.

stress urinary incontinence (sui) is defined by the international continence society (ics) as an involuntary loss of urine on physical exertion, sneezing, or coughing (1). it occurs primarily in multiparous women (2). the prevalence of ui among egyptian women is high (55%). aging, low educational level, menopause, higher parity (\>3), vaginal delivery, and previous multiple abortions (\>3) are significant risk factors for ui(3) mid-urethral slings (tvt and tot) are now the recognized worldwide standard of care for the surgical treatment of stress urinary incontinence(4) (5) mid-urethral slings have a very high satisfaction rate (85-90 %) (4) (6), with durability of satisfaction recently demonstrated out to 5-years (79-85 %) as well as a modest 5-year treatment success (43-51 %) (4, 7) burch colposuspension is a well-accepted technique for surgical management of stress urinary incontinence (sui), especially when it is associated with urethral hypermobility. it first description in 1961 (8) (9) originally performed as an open surgical procedure and then over time, burch colposuspension has been adapted for laparoscopy, it was long considered as the "gold standard" for the treatment of sui before emergent of midurethral slings (9) the cure rates for laparoscopic colposuspention is as high as 68.9% to 88.0% whereas recurrence rates remain low, however, it has been reported that the cure rate of retropubic suspension techniques in general decreases steadily from 90% at 1 year to about70% by 10 years postoperatively. after a decline, it seems to reach a plateau at 65-70% at a 20 year follow-up (9) after the food and drug administration (fda) issued a warning about the use of transvaginal meshes for pelvic organ prolapse (pop) in 2011, there has been much debate about the use of mesh in the mus continence procedures. concern is increasing that the use of transvaginal mesh devices to treat sui and pop have exposed women to avoidable harms following complications such as infection, tissue extrusion, mesh exposure ,mesh shrinkage, and side effects such as severe pain, sexual dysfunction, and repeat surgical interventions (5).

Eligibility criteria:
inclusion criteria: * 1- all adult female patients complaining of stress urinary incontinence attending the voiding dysfunction clinic at asyut urology and nephrology hospital and willing to participate in the study. exclusion criteria: * 1- recurrent sui. 2- significance pelvic organ prolapse requiring surgical intervention. 3- associated neurologic disorders affecting the lower urinary tract e.g diabetes, spinal cord injury and others.
study to determine the safety and preliminary efficacy of cc-1088 in the treatment of myelodysplastic syndromes

Conditions: Myelodysplastic Syndrome

Summary: the primary objective of the study is to assess the safety of cc-1088 to patients with myelodysplastic syndromes (mds).


Eligibility criteria:
inclusion criteria: * eligible patients must have a diagnosis of mds of at least 12 weeks that is not therapy related. * age ≥ 18 at the time of signing informed consent * patient must be able to adhere to the study visit schedule and other protocol requirements. * patient must understand and voluntarily sign an informed consent document. * women of childbearing potential (wcbp) must have a negative serum or urine pregnancy test. * sexually active wcbp must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner). * women must not be pregnant or lactating. exclusion criteria * pregnant and lactating women and wcbp who are not using adequate contraception. * myelosclerosis (or myelofibrosis) occupying \>30% of marrow space * patients with iron deficiency (e.g., absent bone marrow iron store). if a marrow aspirate is not evaluable for storage iron, transferrin saturation must be 220% and serum femtin not less than 50 ng/ml. * patients with uncorrected bl2 or folate deficiency. * patients with contributing causes of anemia such as autoimmune or heredity, hemolytic disorders, or gi blood loss. * patients with a history of malignancy, except basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ. * patients with clinically significant, symptomatic and unstable pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal or genitourinary system diseases unrelated to their underlying hematologic disorder. * life-threatening or active infection requiring parenteral antibiotic therapy or other serious concurrent illness. * patients who have a history of testing positive for hepatitis b surface antigenemia,'hepatitis c, or hiv. * inadequate organ hction: renal insufficiency \[serum creatinine levels \>1.5 x upper limit of normal (uln)\] or hepatic impairment (bilirubin 22 mg/dl or ast/alt 22 x uln). * patients may not have received another investigational study drug within 30 days of entry in the present study. * requirement for ongoing therapy with corticosteroids.

Keywords: myelodysplastic syndrome
effectiveness of basketball pre-injury attack program to reduce the susceptibility of injury in youth basketball players

Conditions: Injury;Sports; Biomechanical Lesions; Musculoskeletal Injury; Sports Physical Therapy

Summary: basketball is an impact, coordination-opposition sport with continuous contact among players and it is considered a sport of medium-high injury incidence. players are force to have a physical condition appropriate to their practice and the demand to which they must respond due to the intensity of the efforts this sport requires. in order to achieve this, it is necessary to establish an evaluation protocol that allows the detection of functional deficiencies, to guide and conduct in a specific and early way every moment of players' health and growth. the purpose of this study is to design, apply and analyze the effectiveness of a specific and individualized therapeutic exercise program (basketball pre-injury attack) based on the approach of the functional deficiencies detected by the basketball injury defense, to reduce the susceptibility to injury of youth basketball players (u14 - u17).

the aim of this study is to design, apply and analyze the effectiveness of a specific and individualized therapeutic exercise program (basketball pre-injury attack) based on the approach of functional deficiencies detected by the basketball injury defense, to reduce the susceptibility to injury of training federated basketball players. the specific objectives are: to improve the deficiencies detected in mobility, stability, symmetry and jumping/landing technique of basketball players in training categories (u14, u16 and u17). to structure and determine the contents of a specific and individualized therapeutic exercise program (basketball preinjury attack) designed to improve the functional deficiencies of mobility, stability, symmetry and jumping/landing technique of training basketball players based on current scientific evidence. to analyze whether adherence to the program is achieved by raising players' awareness of the importance and benefits of performing the exercises with correct technique. to assess whether a decrease in the susceptibility to injury of training federated basketball players is achieved. for this purpose, an experimental study was conducted as a single-blind, randomized, cluster-controlled clinical trial during the months of june 2019 to february 2020 (9 months). for the development of the methodology of this study, the guidelines of the consort (consolidated standards of reporting trials) statement were followed.

Eligibility criteria:
inclusion criteria: * be between 10 and 17 years old * be an active player at the time of selection * sign the informed consent. exclusion criteria: * being diagnosed with a psychological and/or psychiatric illness. * being diagnosed with an oncological disease. * be injured at the time of selection.

Keywords: basketball prevention